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Introduction
============

Fibronectin (FN)[\*](#fn1){ref-type="fn"} functions from within a fibrillar matrix, and proper formation of matrix fibrils is crucial for controlling tissue structure and cell motility, growth, and differentiation ([@bib20]; [@bib11]; [@bib24]). Multiple FN domains have been implicated in intermolecular interactions required for the assembly process, including FN\'s dimer structure and NH~2~-terminal assembly domain ([@bib17]; [@bib15]; [@bib23]). Integrin binding to the arg-gly-asp (RGD) cell binding sequence within the cell binding domain is necessary for initiation of fibril formation, but not for fibril elongation ([@bib27]). In the absence of the synergy site, α5β1-mediated assembly is stalled, suggesting that fibril growth requires strong interactions between FN and integrins ([@bib25]). This is further supported by the demonstration that activation of α4β1, αvβ3, and αIIbβ3 integrins can promote FN assembly ([@bib33], [@bib34]; [@bib31]; [@bib26]).

FN--FN interactions are also important for fibril formation. The major site of interaction is the NH~2~-terminal assembly domain which consists of repeats I~1--5~ and binds FN and many other molecules ([@bib20]; [@bib11]; [@bib23]). Other FN binding sites have been localized to the first one or two type III repeats ([@bib18]; [@bib1]; [@bib9]; [@bib12]), the cell binding repeat III~10~ ([@bib10]), and the COOH-terminal heparin binding domain (III~12--14~) ([@bib3]). Each of these sites interacts with the NH~2~-terminal assembly domain.

Results from binding, inhibition, and matrix assembly studies show that FN fibrils form via a multistep process ([@bib16]; [@bib24]). During the initiation stage of assembly, integrin binding immobilizes dimeric FN and promotes formation of deoxycholate (DOC)-soluble fibrils in a process that depends on the NH~2~-terminal assembly domain. Mutations that affect the RGD cell binding sequence or the NH~2~-terminal domain ablate fibril formation ([@bib23]; [@bib28]; [@bib27]; [@bib29]). Assembly then progresses into a growth phase that involves incorporation of additional FN dimers into nascent fibrils, fibril elongation, and conversion of fibrils into a DOC-insoluble form. The matrix is further stabilized as DOC-insoluble FN is formed into high molecular mass multimers.

We have shown previously that a recombinant FN (recFN) lacking the first seven type III repeats (FNΔIII~1--7~) is able to form a fibrillar matrix, albeit at an altered rate ([@bib27]). It appears that this set of seven repeats, or a subset of them, has a regulatory role in FN assembly. In this study, recFNs containing overlapping deletions across this region were tested for the ability to form fibrils, DOC-insoluble matrices, and high molecular mass multimers. Surprisingly, deletion of repeat III~1~, a site proposed to be essential for assembly, had no detrimental effects on assembly. Similarly, relatively large deletions of up to four type III repeats, as well as displacement of the cell binding domain toward the NH~2~ terminus, caused no deficiencies in matrix formation. However, deletions that included repeat III~2~ reduced the assembly of a DOC-insoluble matrix and blocked fibril elongation. Binding studies using recombinant fragments showed that III~2~, but not III~1~, has FN binding activity. Our results indicate that repeat III~2~ is a key element in the regulation of FN--FN interactions during matrix assembly.

Results
=======

Repeat III~1~ is not essential for FN assembly
----------------------------------------------

To delineate the elements involved in the regulation of FN matrix assembly, a set of recFNs containing in-frame deletions within the first seven type III repeats was prepared ([Fig. 1](#fig1){ref-type="fig"}) . Of particular interest was the first type III repeat, which has FN binding activity when in denatured form and has been implicated in FN matrix formation ([@bib18]; [@bib1]; [@bib9]; [@bib12]). Using the baculovirus expression system, FNΔIII~1~ was expressed from a rat FN cDNA mutated by PCR to eliminate the entire segment encoding repeat III~1~. Assembly was tested using CHO K1 cells transfected with human α5 integrin cDNA (CHOα5) that do not assemble an endogenous matrix ([@bib27]). FNΔIII~1~ was assembled into a fibrillar matrix morphologically identical to that formed by native FN ([Fig. 2](#fig2){ref-type="fig"} , A--D) or full-length recFNA-B- (unpublished data and [@bib27]). No differences in native and FNΔIII~1~ matrices were detected at any of the time points studied. AtT-20 mouse pituitary cells transfected with human α5 integrin cDNA (AtT-20α5), a cell line that does not express any endogenous FN ([@bib27]), also assembled morphologically identical native and FNΔIII~1~ matrices ([Fig. 2, E and F](#fig2){ref-type="fig"}). Therefore, in two independent cell lines, FN matrix assembly was not altered by the deletion of repeat III~1~.

![**Schematic representation of FN and recFNs.** The structural organization of FN consisting of type I (rectangles), type II (triangles), and type III (ovals) repeats is shown at top. Darkened ovals represent alternatively spliced EIIIA and EIIIB repeats that were not included in any recFNs. All recFNs contain the V120 variant of the alternatively spliced V region (cross-hatched box) as well as the COOH-terminal cysteine pair (S-S). The inverted triangle over FNrIII~4--5/9--10~ indicates a deleted RGD sequence; white ovals are III~9--10~ in place of III~4--5~. All six recFNs were constructed from rat FN cDNA.](0102034f1){#fig1}

![**Assembly of FN**Δ**III~1~.** CHOα5 cells were cultured in the presence of 50 μg/ml pFN (A and B) or 50 μg/ml FNΔIII~1~ (C and D) for 4 (A and C) or 16 (B and D) h. AtT-20α5 cells were incubated with 25 μg/ml pFN (E) or FNΔIII~1~ (F) for 16 h. Cells were then fixed and FN fibrils detected by indirect immunofluorescence with monoclonal anti--rat FN antibody IC3. Bar, 10 μm.](0102034f2){#fig2}

Biochemically, FNΔIII~1~ and native FN matrices were indistinguishable. Equivalent amounts of both proteins were associated with CHOα5 cells in the DOC-soluble fractions ([Fig. 3](#fig3){ref-type="fig"} A). Similar proportions of DOC-insoluble material were formed from FN and FNΔIII~1~ during a 16-h incubation ([Fig. 3](#fig3){ref-type="fig"} B). As has been shown previously for FN ([@bib16]; [@bib27]), there was continued incorporation of FNΔIII~1~ into DOC-insoluble matrices and high molecular mass aggregates ([Fig. 3](#fig3){ref-type="fig"} B, 48 h). These data show that III~1~ is neither required for the formation of fibrils, nor responsible for the altered rate of assembly observed with FNΔIII~1--7~.

![**DOC-soluble and -insoluble FN**Δ**III~1~.** CHOα5 cells were incubated with 50 μg/ml pFN or FNΔIII~1~ for the indicated times and lysed in buffered DOC. DOC-soluble (A) and -insoluble (B) fractions were separated in 5% polyacrylamide-SDS gels without reduction and transferred to nitrocellulose. FN was detected on immunoblots with monoclonal anti-FN antibody IC3 and chemiluminescence reagents. Dimeric pFN and FNΔIII~1~ are present (arrowhead) as well as high molecular mass multimers at the top of the stacking (bracket) and at the interface of the stacking and separating gels (arrow).](0102034f3){#fig3}

Reduced matrix accumulation in the absence of repeats III~2--5~
---------------------------------------------------------------

In contrast to the normal matrix formed with FNΔIII~1~, deletion of III~2--5~ decreased matrix accumulation. Some fibril assembly was initiated, but the amount of FNΔIII~2--5~ matrix assembled by CHOα5 cells was less than that of native FN, and the distribution of fibrils was more sparse than for native FN ([Fig. 4](#fig4){ref-type="fig"} A). Furthermore, DOC-insoluble matrix was at least threefold less for FNΔIII~2--5~ than for native FN ([Fig. 4](#fig4){ref-type="fig"} B). Limited conversion of DOC-soluble FNΔIII~2--5~ into DOC-insoluble matrix suggests that this recFN is impaired in its ability to participate in fibril growth.

![**Assembly of FN**Δ**III~2--5~.** (A) Native pFN and FNΔIII~2--5~ were added to CHOα5 cells at a concentration of 50 μg/ml and cultured for the indicated times. Fibrils were visualized by indirect immunofluorescence as in [Fig. 2](#fig2){ref-type="fig"}. (B) DOC-insoluble material isolated at the indicated times was analyzed under reducing conditions by immunoblotting with IC3 monoclonal antibody. Bar, 10 μm.](0102034f4){#fig4}

Analyses of the assembly of two other deletion mutants, FNΔIII~4--5~ and FNΔIII~4--7~, showed formation of characteristic fibrils at all time points (unpublished data). Furthermore, biochemical analyses did not reveal any defects in incorporation into DOC-insoluble matrix or the formation of high molecular mass multimers, results similar to those observed for FNΔIII~1~. FNΔIII~2--5~ and FNΔIII~4--7~ both lack four type III repeats but differ in their capacity to be assembled. This indicates that alterations in the ability to assemble matrices cannot be attributed solely to the size of the deletion. Instead, there appear to be specific roles for individual type III repeats and normal assembly of FNΔIII~4--5~ compared with FNΔIII~2--5~ indicates that III~2~ and/or III~3~ may be important.

Fibril growth depends on repeats III~1--2~
------------------------------------------

Because III~1--2~ has FN binding activity ([@bib1]) and a proteolytic fragment containing III~1~ plus part of III~2~ inhibits incorporation of FN into matrix ([@bib6]; [@bib18]), we generated FNΔIII~1--2~ to test whether these two repeats together comprise a matrix regulatory region. Immunofluorescence analysis of FN assembled by CHOα5 cells showed that early during assembly, FNΔIII~1--2~ formed aggregates on the cell surface ([Fig. 5](#fig5){ref-type="fig"} A) similar to, but much smaller than, those formed by FNΔIII~1--7~ ([@bib27]). As assembly progressed, FNΔIII~1--2~ formed mainly short fibrils between cells although occasional long thin fibrils were also visible. An extensive fibrillar network was never observed even after prolonged incubations. Levels of DOC-insoluble material were significantly reduced, especially at later times of assembly, and no high molecular mass multimers were observed ([Fig. 5](#fig5){ref-type="fig"} B). Incubations with higher concentrations of FNΔIII~1--2~ did not increase the amount of DOC-insoluble matrix (unpublished data). Unlike FNs lacking the RGD sequence, FNΔIII~1--2~ was not deficient in binding to cells. In fact, substantially more FNΔIII~1--2~ than native FN was isolated as cell-associated DOC-soluble material. This indicates that FNΔIII~1--2~ can efficiently bind to the cell surface to initiate assembly, but is defective in the growth phase when conversion from DOC-soluble to -insoluble matrix occurs.

![**Assembly of FN**Δ**III~1--2~.** (A) CHOα5 cells were incubated for either 4 or 24 h in the presence of 50 μg/ml FNΔIII~1--2~. Monoclonal antibody IC3 was used to detect recFN matrix by immunofluorescence. (B) DOC-soluble and -insoluble cell lysates were isolated from CHOα5 cells incubated in the presence of 50 μg/ml FNΔIII~1--2~ or pFN for 0.5, 4, 7, 16, 24, and 48 h. DOC-soluble and -insoluble material was analyzed as described in [Fig. 3](#fig3){ref-type="fig"}. Arrow and bracket indicate locations of high molecular mass multimers. Dash indicates location of 180-kD molecular mass standard. Bar, 10 μm.](0102034f5){#fig5}

FN lacking the RGD sequence is unable to initiate matrix assembly but can be incorporated once assembly has been primed by native FN ([@bib27]). However, preinitiation by native FN would not be expected to rescue FNΔIII~1--2~ assembly, as this protein shows a defect in fibril growth. In fact, neither FNΔIII~1--2~ nor FNΔIII~2--5~ was able to efficiently incorporate into a preformed human FN matrix. A very few short fibrils were formed by FNΔIII~1--2~ ([Fig. 6](#fig6){ref-type="fig"} B) and FNΔIII~2--5~ fibrils were found in small patches distributed unevenly throughout the matrix ([Fig. 6](#fig6){ref-type="fig"} C). In contrast, an extensive fibrillar network was assembled by native FN ([Fig. 6](#fig6){ref-type="fig"} A). In all cases, a fibrillar human plasma FN (pFN) matrix could be readily detected with a human FN-specific monoclonal antibody (unpublished data). Thus, the presence of repeat III~2~ is required for the continued growth of FN fibrils.

![**RecFN assembly in the presence of human FN matrix.** CHOα5 cells were incubated with 50 μg/ml human pFN for 8 h. Medium was then removed, cell layers were washed to remove unbound FN, and cells were fed with fresh medium containing 25 μg/ml full-length recFN (A), FNΔIII~1--2~ (B), or FNΔIII~2--5~ (C). After incubation for an additional 16 h, cells were fixed and recFN fibrils detected with an anti--rat FN-specific monoclonal antibody. Bar, 20 μm.](0102034f6){#fig6}

Repeat III~2~ contains an FN binding site
-----------------------------------------

To demonstrate a requirement for III~2~ in FN assembly, attempts were made to generate a recFN lacking repeat III~2~ or with another homologous repeat in its place. Unlike the recFNs reported here, secretion of mutant recFNs lacking III~2~ from infected insect cells was very inefficient, suggesting that in the absence of this repeat the proteins were not properly folded. We have shown previously that III~1--2~ purified in soluble form from bacterial lysates is able to bind FN ([@bib1]). To identify the repeat responsible for FN binding activity, maltose-binding protein (MBP) fusion proteins containing either III~1~ or III~2~ were generated and tested for binding in solid phase binding assays. MBP-III~2~, but not MBP-III~1~, showed significant FN binding activity ([Fig. 7](#fig7){ref-type="fig"} A) that was reversed by treatment with buffered SDS (unpublished data). The lack of MBP-III~1~ binding confirms the results of [@bib12] who showed that native III~1~ does not bind to FN or its fragments. FN binding was concentration dependent and a complementary binding site was localized to the 70-kD region ([Fig. 7](#fig7){ref-type="fig"} B). Apparent dissociation constants for FN and 70 kD binding to III~2~ differ by only 3.5-fold, 28 nM, and 8 nM, respectively. The higher dissociation constant for FN may reflect a difference in affinity. However, it may also be due to molecular differences between the relatively small 70-kD fragment and dimeric pFN, which has a compact conformation that may reduce accessibility to III~2~ binding sites.

![**Repeat III~2~ contains a FN binding site.** Solid phase binding assays were used to examine binding of FN (A--C) and NH~2~- terminal 70-kD fragment (B) to immobilized fusion proteins. (A and C) MBP and fusion proteins were coated at 2 μg/ml and incubated with 50 μg/ml rat pFN. (B) MBP-III~2~ coated at 4 μg/ml was incubated with rat pFN or 70-kD fragment at increasing concentrations. Background binding to MBP was subtracted from these data. Binding was detected with 5G4 anti-FN monoclonal antibody for FN (A and C) or R457 anti--70-kD polyclonal antiserum (B). Results are presented as the average of normalized values from two to three experiments.](0102034f7){#fig7}

Between III~1~ and III~2~ is a 17--amino acid "linker" segment that was present in the MBP-III~2~ protein. To determine whether the binding site was located in the type III repeat or the linker, an MBP protein was generated containing III~1--2~ but lacking the linker (MBP-III~1--2~ΔL) and tested for FN binding. MBP-III~1--2~ΔL bound to FN ([Fig. 7](#fig7){ref-type="fig"} C) and the 70-kD fragment (unpublished data) to an extent identical to MBP-III~1--2~. Similar III~1--2~ and III~1--2~ΔL fragments prepared from human FN also showed concentration-dependent binding to 70 kD (unpublished data). Therefore, the site resides in III~2~ itself and is present in both rat and human FNs. These results identify repeat III~2~ as a major FN binding site and suggest that the lack of fibril formation by FNΔIII~1--2~ is due to the absence of this site.

Repositioning of III~9--10~ cell binding domain
-----------------------------------------------

The cell binding domain consisting of an RGD sequence and synergy site in repeats III~9--10~ is essential for initiation of FN matrix assembly by α5β1 integrin ([@bib27], [@bib25]). Deletions within repeats III~1--7~ position the cell binding domain closer to the NH~2~-terminal assembly domain and could affect recFN fibril formation. To eliminate the possibility that changes in the domain organization can alter FN assembly, we created FNrIII~4--5/9--10~. Repeats III~4--5~ were replaced with III~9--10~ and the RGD sequence was deleted from its native position within the cell binding domain ([Fig. 1](#fig1){ref-type="fig"}). Therefore, the only functional III~9--10~ pair is in the position normally occupied by III~4--5~. CHOα5 cells efficiently assembled FNrIII~4--5/9--10~ into a DOC-insoluble fibrillar matrix identical to that of native FN at all time points ([Fig. 8](#fig8){ref-type="fig"} , A--C). Cell cycle progression by CHOα5 cells assembling either FN or FNrIII~4--5/9--10~ was identical, as were the levels of focal adhesion kinase phosphorylation (unpublished data). These results demonstrate that the location of the cell binding domain is not restricted to the center of the molecule and that displacement toward the NH~2~ terminus does not reduce FN function in matrix assembly or its ability to influence cell cycle progression.

![**Assembly of FNrIII~4--5/9--10~.** CHOα5 cells were cultured in the presence of 50 μg/ml FNrIII~4--5/9--10~ for 4 (A) and 16 (B) h. (C) DOC-insoluble material was isolated from CHOα5 cells 4 and 16 h after incubation with 50 μg/ml FNrIII~4--5/9--10~ and analyzed as in [Fig. 3](#fig3){ref-type="fig"}. Locations of high molecular mass multimers are indicated with arrow and bracket. 180-kD molecular mass standard is indicated by dash. Bar, 10 μm.](0102034f8){#fig8}

Discussion
==========

FN fibril assembly is initiated by binding to integrin receptors and propagated by FN--FN interactions. The progression of FN conversion from soluble dimer into insoluble matrix fibrils is regulated in part by sequences within repeats III~1--7~ ([@bib27]). Using a set of overlapping deletions within this region, we have identified repeat III~2~ as an important FN binding site involved in fibril elongation. Deletions spanning this repeat severely limit fibril assembly and block formation of DOC-insoluble material. In addition to implicating III~2~, our results also eliminate several candidate sites as important contributors to this process. Specifically, we have shown that: (a) the III~1~ repeat and its cryptic FN binding site are not needed for fibril formation; (b) relatively large deletions of as many as four repeats do not affect fibril assembly; and (c) there is considerable pliability in the location of the cell binding domain. None of the deletions tested here had an obvious effect on FN binding to integrins or initiation of fibril assembly, indicating that reported interactions between III~1~ and the cell binding domain ([@bib10]) are not required in the early stages of FN matrix assembly.

Our data with FNΔIII~1--2~ and FNΔIII~2--5~ show that repeat III~2~ participates in the growth phase of FN assembly. Assembly was initiated by both of these recFNs but DOC-insoluble matrix formation was blocked. Together with data showing a direct interaction between III~2~ and the NH~2~-terminal assembly domain of FN, our matrix assembly results indicate that this FN binding site plays a key role in FN--FN interactions during fibril assembly. Repeats III~2--3~ have been shown previously to interact with repeats III~12--14~, an interaction that appears to contribute to the formation of the compact conformation of soluble FN ([@bib13]). Thus, the III~2~ module may participate in matrix assembly through interactions with several sites on FN. These interactions may promote elongation by aligning fibrils into a stable, uniform structure that can then be converted into a DOC-insoluble form. In the absence of this repeat, fibrils begin to form but become stalled during elongation and are inefficiently converted into the DOC-insoluble matrix. DOC-insolubility of FN fibrils appears to occur through hydrophobic protein--protein interactions that resist SDS denaturation ([@bib4]). Perhaps III~2~ participates in the formation of that hydrophobic interface.

Others have shown the presence of a cryptic FN binding site in III~1~ that is exposed by denaturation ([@bib9]; [@bib12]). The apparent affinity of 70 kD for III~2~ is higher than that reported for 70 kD binding to heat-denatured III~1~ ([@bib9]). The identification of two distinct sites indicates that the III~1--2~ segment contains more than one FN binding site, the site in III~2~ that is critical for fibril assembly and a cryptic site in III~1~ that is dispensable for this process. It is also possible that repeats III~1--2~ act as a functional unit to regulate fibril assembly and promote elongation. For example, interactions between III~1~ and III~2~ could regulate the accessibility of an FN binding site. Previous studies lend support to the idea of cooperation between these repeats. Both repeats were required for formation of an in vitro ternary complex with heat-denatured III~10~ and the NH~2~-terminal 70-kD fragment ([@bib10]). III~2~ has also been proposed to contribute to interactions between III~1~ and the COOH-terminal heparin binding domain ([@bib3]). Furthermore, the reduced secretion of recFNs lacking III~2~ or carrying another type III repeat in place of III~2~ indicates that interactions between adjacent repeats contribute to domain structure and stability. III~1~-specific inhibitory peptides and antibodies have been described ([@bib5], [@bib6]; [@bib18]). If III~1~ and III~2~ do indeed function together, these inhibitory reagents may exert their effects indirectly through disruption of activities mediated by the adjacent III~2~ module.

Regulated assembly depends in part on conformational changes in the FN molecule. Accumulating evidence indicates that soluble FN dimers must be converted from a compact inactive form into an "unfolded" activated form in order for assembly to proceed ([@bib2]; [@bib32]; [@bib8]; [@bib22]; [@bib30]; [@bib24]). In vivo, integrin binding induces FN activation and this may expose the III~2~ binding site, allowing intermolecular interactions between cell surface--bound FNs. Whereas recFNs lacking III~2~ are able to initiate assembly and form short fibrils, the significantly reduced levels of DOC-insoluble FNΔIII~1--2~ suggest that in the absence of the III~2~ binding site, this recFN cannot effectively participate in the essential FN--FN interactions needed for fibrillogenesis. FN molecules can also be induced to associate in solution by the addition of a peptide corresponding to part of the III~1~ module ([@bib19]). This treatment may expose the III~2~ binding site by local perturbation of intramolecular interactions involving this region of the molecule.

Comparison of the progression of assembly by FNΔIII~1--2~ with FNΔIII~1--7~ shows that both initially form short stitches around cell peripheries and connect to adjacent cells. FNΔIII~1--7~ then forms aggregates that prematurely become insoluble in DOC ([@bib27]). These aggregates can apparently be remodeled by binding to adjacent cells and getting stretched into fibrils. In this way, FNΔIII~1--7~ forms a relatively normal-appearing fibrillar matrix. On the other hand, FNΔIII~1--2~ forms only a few small, DOC-soluble aggregates that can be converted into predominantly short fibrils. FNΔIII~1--2~ does not accumulate in DOC-insoluble material, nor does it form an extensive fibrillar matrix. The differences between assembly of FNΔIII~1--2~ and FNΔIII~1--7~ suggests that repeats III~3--7~ contribute to the progression of FN fibril formation. A few activities have been mapped to the III~3--7~ region. Repeats III~4--6~ can bind to heparin and DNA under low salt conditions ([@bib11]). Cryptic binding sites within repeat III~5~ have been reported for activated α4β1 and α4β7 integrins ([@bib21]) as well as for repeat III~1~ ([@bib10]). Repeat III~1~ can also bind to repeat III~7~ ([@bib12]). Thus, it is possible that during assembly this region of FN interacts with cell surface or matrix proteins or glycosaminoglycans, and that these interactions may help to control fibril formation.

FNΔIII~1--2~ and FNΔIII~1--7~ probably also differ in the alignment of FN dimers into fibrils. For example, binding of the NH~2~-terminal assembly domain of one FNΔIII~1--7~ dimer to the COOH-terminal heparin domain of another ([@bib3]) would align their cell binding domains relatively close to each other. This juxtaposition could result in increased clustering of integrins and more stable contacts between matrix and cytoskeleton, giving the strong connections needed to remodel aggregates into fibrils and form DOC-insoluble material. Tension applied to FN fibrils has been predicted to cause slight unfolding of type III repeats ([@bib7]; [@bib14]), and this might allow the formation of SDS-resistant protein--protein interactions ([@bib4]). On the other hand, the inclusion of III~3--7~ may yield a potentially different organization of both cell surface receptors and cytoskeletal elements, thus precluding the formation of a stable matrix.

Clearly, multiple options exist for establishing FN--FN interactions during matrix assembly. For example, the NH~2~-terminal assembly domain is required throughout the assembly process, whereas the III~2~ module participates after initiation during a phase of fibril growth. This indicates that different FN binding sites have distinct temporal and spatial roles, and suggests that control of domain-specific FN interactions may play an important role in regulating the structural and functional organization of the FN matrix.

Materials and methods
=====================

Cell culture
------------

CHOα5, clone 17, and AtT-20α5, clone 11, transfected with a cDNA to the human α5 integrin subunit have been described previously ([@bib27]). For all experiments, CHOα5 cells were cultured in DME supplemented with 2 mM glutamine, 1% nonessential amino acids, 100 μg/ml Geneticin (Life Technologies/GIBCO BRL), and 10% fetal calf serum (Hyclone Labs) depleted of FN. AtT-20α5 cells were cultured in a 50:50 mixture of Ham\'s F12 and DME, plus 20 mM Hepes, pH 7.4, 4 mM glutamine, 0.25 mg/ml Geneticin (Life Technologies/GIBCO BRL), and 10% fetal calf serum (Hyclone Labs) and 10% Nu-serum both depleted of FN.

FN cDNA constructions and recombinant protein production
--------------------------------------------------------

All recFNs were expressed with baculovirus vector pVL1392. Restriction enzymes and T4 DNA ligase were purchased from New England Biolabs, Inc. Oligonucleotide primers were prepared by the Synthesis and Sequencing Facility (Princeton University, Princeton, NJ).

All deletions were created by PCR amplification of rat FN cDNA. A KpnI site was engineered into each oligonucleotide to join the regions spanning each deletion. PCR amplification for 25 cycles was performed for all constructions under the following conditions: 95°C, 30 s; 60°C, 60 s; and 72°C, 60 s. PCR products were digested with flanking enzymes and inserted into the FN cDNA using convenient restriction sites. The following 5′ and 3′ primers were used to generate the indicated deletions (base positions of the primers within the FN cDNA are in parentheses and base changes to introduce the Kpn I sites are underlined): ΔIII~1~: GG[GGT]{.ul}A[CC]{.ul}TGTGCCTGGGTA (1831-1812), CTG[GT]{.ul}ACCAGCAACACAGTG (2116-2130); ΔIII~4--7~: CGGG[T]{.ul}AC[C]{.ul}TCATCGGATCGT (2721-2702), GC[G]{.ul}GT[A]{.ul}CCTCCTCCCACGGA (4065-4084); ΔIII~2--5~: TGTTGCTGG[GT]{.ul}AC[C]{.ul}GGTGTG (2124-2105), CCTG[GTA]{.ul}CCTCTGCGCTCCA (3248-3267). pVL1392 FNΔIII~1--2~ was prepared by ligating a fragment from FNΔIII~1~ with a PCR-amplified fragment made using the primer CTGGTACC[G]{.ul}CACCTGATGCGCCTCCAG (2424-2442). pVL1392 FNΔIII~4--5~ was created by ligating a 5′ fragment from pVL1392 FNΔIII~4--7~ with a 3′ fragment from pVL1392 FNΔIII~2--5~. To generate pVL1392 FNrIII~4--5/9--10~, a segment spanning repeats III~9--10~ was amplified using 5′ primer GA[GGTACC]{.ul}GGACTCCCCAACTGGTTTTG (4552-4570) and 3′ primer GA[GGTACC]{.ul}GCTGTTTGATAATTGATGGAAACTGGC (5098-5073) containing KpnI sites (underlined). The resulting KpnI fragment was then inserted at the engineered KpnI site in pVL1392 FNΔIII~4--5~ and a segment encoding an RGD deletion was inserted into the cell binding domain ([@bib23]). All regions obtained from PCR products were verified by DNA sequence analysis.

Recombinant baculoviruses were created and recombinant proteins and rat pFN were purified as described ([@bib27], [@bib25]). Yields of recFNs were at least 0.8 mg/100 ml of culture supernatant. The identity of FNΔIII~1~ and FNΔIII~1--2~ recombinant baculoviruses was further confirmed using DNA isolated from infected High Five insect cells as template for PCR amplification with flanking primers. Correctly sized PCR products were obtained as analyzed by PAGE before and after restriction with KpnI.

Immunofluorescence
------------------

As described in [@bib27], CHOα5 and AtT-20α5 cells were seeded in medium containing FN-depleted serum and plated onto glass coverslips in a 24-well dish or four-well chamber slides at a concentration of 1.5 × 10^5^ and 4 × 10^5^, respectively. After an overnight incubation, fresh medium was added along with either pFN or purified recFN and incubated for the times indicated. Cell layers were fixed with 3.7% formaldehyde and stained with a 1:1,000 dilution of IC3 ascites in PBS with 2% ovalbumin followed by a 1:400 dilution of fluorescein-conjugated goat anti--mouse secondary antibody. Stained cells were mounted with FluoroGuard (Bio-Rad Laboratories), and fibrils were visualized with a Nikon Optiphot-2 microscope. Images were collected with a DEI-750 cooled CCD camera (Optronics Engineering) and transferred to a Macintosh G3 computer with an LG3 frame grabber (Scion Corp.) and Adobe Photoshop v. 5.0.

Isolation and detection of DOC-soluble and -insoluble matrix
------------------------------------------------------------

DOC-soluble and -insoluble material was isolated from CHOα5 cells cultured in a 24-well dish with pFN or recFNs as described above. After the indicated time periods, cells were washed with serum-free DME and lysed with 200 μl of DOC lysis buffer (2% deoxycholate, 0.02 M Tris-HCl, pH 8.8, 2 mM phenylmethylsulfonyl fluoride, 2 mM EDTA, 2 mM iodoacetic acid, and 2 mM N-ethylmaleimide) per well. Lysates were separated into DOC-soluble and -insoluble fractions that were analyzed by SDS-PAGE. Immunodetection was performed as described ([@bib27]) using ascites fluid from rat FN--specific monoclonal antibody IC3 at a dilution of 1:1,000. Immunoblots were developed with Super Signal chemiluminescence reagents (Pierce Chemical Co.). Band intensities were quantified at two exposure times using IPLab software (Mac v. 3.5; Scanalytics, Inc.).

Expression of bacterial fusion proteins and FN binding assays
-------------------------------------------------------------

Rat FN cDNA fragments encoding repeat III~1~ or III~2~ were inserted into pMAL-cRI (New England Biolabs, Inc.) for expression as MBP fusion proteins. III~1~ spanned amino acid positions 604--700 (TYP ... TTS) and III~2~ extended from residue 701 to 808 (AST ... QTT). BamHI sites and XbaI sites were engineered at the 5′ and 3′ ends, respectively. PCR amplification using primers homologous to sequences flanking the 17--amino acid linker (701--717) was used to replace these residues (AST ... APF) with a KpnI site to generate III~1--2~ΔL. *Escherichia coli* TB1 cells expressing individual MBP fusion proteins were lysed with B-PER (Pierce Chemical Co.) and proteins were purified by amylose resin affinity chromatography following the manufacturer\'s recommendations. Rat pFN, recombinant 70-kD fragment, MBP, and MBP-III~1--2~ were purified as described previously ([@bib1]).

Solid phase binding assays were performed essentially as described by [@bib1]. Fusion proteins containing III~1~, III~2~, III~1--2~, and III~1--2~ΔL were immobilized on Nunc Maxisorp microtiter plates by overnight incubation at the indicated concentrations. Relative amounts of immobilized proteins were determined by ELISA with an anti-MBP antiserum. After washing and blocking with 1% BSA in PBS, wells were incubated with rat pFN at 50 μg/ml or NH~2~-terminal 70-kD fragment of FN at 30 μg/ml for 2 h at room temperature. Bound FN and 70 kD were detected and quantified by ELISA using anti--rat FN monoclonal antibody 5G4 or anti--70-kD polyclonal antiserum R457.
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